2-STEP: A single-centre, phase II study to evaluate the safety, tolerability and pharmacokinetics of 2-Iminobiotin (2-IB) in neonates with gestational age of ≥36 weeks with moderate to severe perinatal asphyxia treated with therapeutic hypothermia

Trial Profile

2-STEP: A single-centre, phase II study to evaluate the safety, tolerability and pharmacokinetics of 2-Iminobiotin (2-IB) in neonates with gestational age of ≥36 weeks with moderate to severe perinatal asphyxia treated with therapeutic hypothermia

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs 2-iminobiotin (Primary)
  • Indications Asphyxia
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms 2-STEP
  • Most Recent Events

    • 29 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top